33 results about "Choroidal neovascularization" patented technology

The invention discloses a construction method and application of a histopathologic quantitative evaluation model of choroidal neovascularization, and the evaluation model constructed by the method can accurately identify a choroidal neovascularization structure around a laser spot, and can carry out rapid batch analysis on a large number of laid sheets. The reliability and the consistency of analysis results are improved, and differences caused by laser surgery, interference of manual operation factors and the labor cost of analysis are reduced.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention relates to the technical field of medical image processing, in particular to an OCT image choroidal neovascularization segmentation method and system. According to the method, a TransUNet is taken as a reference network, and a heterogeneous feature alignment module, a curvature KAN attention guiding module and a deep and shallow double-path decoder are designed and embedded, so that a choroidal neovascularization segmentation model is constructed. Local features extracted by a convolutional neural network and global context features extracted by a visual extractor are integrated through a heterogeneous feature alignment module, and the network is promoted to comprehensively extract the features of the OCT image; a curvature KAN is used for guiding an attention module to optimize an attention mechanism so as to better acquire local geometric features of the image; the deep and shallow double-path decoder processes deep features and shallow features respectively by constructing two parallel decoding paths, thereby significantly enhancing the ability of the network to capture small target lesions. According to the method, the segmentation precision of the choroidal neovascularization of the OCT image is effectively improved.

The invention belongs to the technical field of biological medicines, and relates to application of an FGF2 inhibitor in preparation of a medicine for treating retina and choroidal neovascular diseases. An oxygen-induced retinopathy (OIR) mouse model and a novel small molecule compound are used for researching related mechanisms in retinopathy neovascularization, and the treatment effect of the small molecule compound is evaluated. Results show that the Refi-10 disclosed by the invention can be used for treating vascular retinopathy by inhibiting FGF2 targets, and a replacement or supplement method of VEGF (vascular endothelial growth factor) inhibiting drugs is provided.

The application discloses a choroid neovascularization image segmentation method based on a hybrid convolutional network, first, collecting fundus OCT scan images and labeling, and forming a data set by using the labeled images; a deep space-time separation hybrid convolutional neural network fusing an attention mechanism is constructed, two-dimensional feature extraction is carried out by using two-dimensional convolution, then the two-dimensional feature extraction is extended to three-dimensional, and then three-dimensional attention deep space-time separation convolution is carried out, and the two-dimensional feature and the three-dimensional feature are aligned and fused; then the hybrid neural network model constructed is trained by using the data set; finally, the trained hybrid neural network model is used to segment choroid neovascularization from the fundus OCT scan images, and a segmentation result is obtained. Through the space-time attention mechanism, local features of the choroid neovascularization image are better extracted, and by using the deep space-time separation convolution, a dimension reduction operation is carried out on the input feature map, so that the calculation parameters can be effectively reduced, thereby reducing the network calculation amount, and the channel attention can be more effectively calculated.

The invention belongs to the technical field of biological medicines, and particularly relates to application of emipril in preparation of a medicine for improving choroidal neovascularization related diseases. The invention aims to solve the problems of strong invasiveness and limited curative effect of the existing therapy. It is found that emipril can achieve differential regulation and control on a CD26 system in vivo, that is, the enzyme activity of CD26 in bone marrow is improved, the enzyme activity of CD26 in peripheral blood is reduced, the concentration gradient of stromal cell-derived factor-1 can be established between the bone marrow and the peripheral blood through differential regulation and control, and the concentration gradient of the stromal cell-derived factor-1 can be further improved. The bone marrow-derived cells are driven to homing to eye lesions and differentiate into repair cells, so that eye diseases are repaired or improved, meanwhile, the collection and migration of bone marrow-derived macrophages to CNV regions can be increased, and the anti-inflammatory effect is achieved. According to the application, an endogenous repair mechanism is activated through non-invasive administration, and a safer and more effective treatment method is provided for related eye diseases.

A method for identifying a type of choroidal neovascularization in a retina of a human eye is disclosed, the method comprising receiving, in a processor, optical coherence tomography data of the eye; generating, in the processor, volume segments of the eye using the optical coherence tomography data and a neural network; and identifying, in the processor, the type of choroidal neovascularization in the eye, using the volume segments, the type of choroidal neovascularization comprising one or more of the following: classic choroidal neovascularization and occult choroidal neovascularization.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

The present invention belongs to the technical field of polymer compounds, and specifically relates to the use of amphiphilic cationic modified mPEG-PCL nanoparticles in the preparation of drugs for treating retinal diseases. The technical problem to be solved by the present invention is the lack of nanomedicines for the treatment of retinal diseases. The technical solution of the present invention is the use of amphiphilic cationic modified mPEG-PCL nanoparticles in the preparation of drugs for treating eye diseases. The nanoparticles of the present invention have low cytotoxicity; can effectively inhibit the development of choroidal neovascularization; and can also be used as carriers for other eye disease-related drugs, enabling combined drug use and the treatment of various eye diseases.

The present invention relates to compounds useful for treating diseases or conditions associated with excessive vascularization of the eye, such as corneal neovascularization, iris neovascularization, ciliary body neovascularization, corneal pannus, choroidal neovascularization, retinal neovascularization, wet age-related macular degeneration, proliferative diabetic retinopathy, retinopathy of prematurity, and ischemic retinopathy.

The invention relates to a heteroaromatic formamide compound and application thereof in medicine. Specifically, the invention relates to a heteroaromatic formamide compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, in particular to application of the compound as a therapeutic agent for plasma kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins, kallikins and kallikins. The present invention relates to the use of a PKa selective inhibitor and to the use in the treatment and / or prevention of diseases that may benefit from plasma kallikrein inhibition, in particular for the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal neovascularization, hereditary angioedema (HAE), cerebral edema after stroke, and the like, and more particularly to the use in the prevention and / or treatment of diabetic macular edema (DME), age-related macular degeneration (AMD), choroidal neovascularization, hereditary angioedema (HAE), cerebral edema after stroke, etc. # imgabs0 #

The present invention discloses an OCT image stratification and lesion semantic segmentation method, device and storage medium. The method comprises: obtaining each BScan two-dimensional slice image data of OCT of one eye of a patient to be examined; inputting the slice image data one by one into a pre-trained first-stage convolutional neural network to obtain the first-stage stratification, optic disc area, and semantic segmentation prediction results of the macula fovea area; making a "region of interest" according to the obtained first-stage stratification, optic disc area, and semantic segmentation prediction results of the macula fovea area; obtaining a data map of the "region of interest"; inputting the data map of the "region of interest" into a second-stage convolutional neural network to obtain the second-stage stratification, drusen, pigment epithelial detachment, and semantic segmentation prediction results of choroidal neovascularization lesions. The present invention increases the proportion of lesion pixels to total pixels and reduces the learning difficulty of small-area positive lesions such as drusen.

Therapeutic agents for CNV only use symptomatic therapies, and have been strongly seeked to be used for radical treatment. In addition, there is no therapeutic agent for dry AMD, and a therapeutic agent for radically treating dry AMD is strongly sought. The present invention provides a prophylactic and / or therapeutic agent for choroidal neovascularization, which contains, as an active ingredient, a compound having an activity of inhibiting epithelial-mesenchymal transition of retinal pigment epithelial cells. Furthermore, the present invention provides a glassy wart inhibitor containing, as an active ingredient, a compound having an activity of inhibiting epithelial-mesenchymal transition of retinal pigment epithelial cells.

A method and system for detecting an advanced stage of age-related macular degeneration in a retina. Optical coherence tomography (OCT) imaging data for a retina is received. A presence of choroidal neovascularization (CNV) in the retina is detected, via a machine learning system, using the OCT imaging data. An output that indicates that the presence of CNV in the retina has been detected is generated.

The invention provides an application of a probiotic lactobacillus reuteri Y7 for protecting eyes. The probiotic lactobacillus reuteri Y7 can be used for preventing or treating eye inflammatory response, cell apoptosis and retina injury of mammals caused by blue light exposure; the damage of blue light exposure to the retina is retinal atrophy or retinal thickness thinning caused by blue light, macular choroidal neovascularization and retinal photosensitive function disability; the damage of the blue light exposure to the retina can cause macular lesion, especially late dry macular lesion. Besides human beings, the Chinese medicinal composition also has curative effects on dogs, cats and other mammals.

The application discloses a dual-specific antibody with functions of inflammation microenvironment regulation and simultaneous inhibition of choroidal neovascularization, and a preparation method and application thereof. The dual-specific antibody is a single-chain antibody, comprises an IL1R, an IL-1 receptor complex auxiliary subunit IL-1RAcP fragment, and extracellular domains D2 (VEGFR2D2) and D3 (VEGFR2D3) of a tyrosine kinase transmembrane receptor VEGFR2, can simultaneously bind to IL-1 and VEGF, has functions of regulating an inflammation microenvironment and inhibiting choroidal neovascularization, and can more accurately treat fundus-related diseases represented by age-related macular degeneration.

The invention discloses application of dihydropyridine in preparation of a medicine for treating choroidal neovascularization, and belongs to the technical field of biological medicines.The proliferation, migration and lumen formation of human choroidal endothelial cells under the hypoxia condition are inhibited through dihydropyridine, and blood vessel leakage, area and volume of laser-induced choroidal neovascularization of mice are reduced; the formation of laser-induced choroidal neovascularization of mice is relieved through dihydropyridine, and the proliferation, migration and lumen formation of hypoxia-induced human choroidal endothelial cells can be down-regulated, so that the PHD has a treatment effect on CNV.

The invention relates to a voxel recognition method, system and device for choroidal neovascularization and a medium. The method comprises the following steps: S1, acquiring a choroidal neovascularization data set; s2, a three-dimensional structure data set is constructed and preprocessed; stacking the two-dimensional cross section image sequences of different light spots into a three-dimensional structure; s3, constructing a model; s4, performing model training; s5, applying the model; and identifying and predicting the choroidal neovascularization data set by using the trained voxel segmentation model, and outputting a prediction result of the choroidal neovascularization for subsequent medical statistical analysis. According to the method, voxel recognition and analysis statistics time of choroidal neovascularization is remarkably shortened, the recognition precision of the model is improved, the resource cost of manpower and material resources is greatly reduced in large-scale clinical tests, the morphology and position of the lesion are analyzed more comprehensively, and misjudgment and area omission caused by human factors are reduced.

The invention relates to a construction method and application of an animal model with retina geographic atrophy (GA) accompanied by choroidal neovascularization (CNV) symptoms. According to the method, sodium iodate is injected at multiple points in the subretinal space of cynomolgus monkeys, so that the retina has typical and clinically close retinopathy GA and CNV symptoms, and the blank of animal models for preclinical evaluation of multi-target drugs for treating GA and CNV at present is filled.

Disclosed is a method of treating a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. Also disclosed is a method of delaying the progression of vision loss in a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. The methods comprise administering an effective amount of gildeuretinol acetate to the patient.

A method for identifying a type of choroidal neovascularization in a retina of a human eye is disclosed, the method comprising: receiving (S1) optical coherence tomography data of the eye in a processor; generating (S2) volume segments of the eye using the optical coherence tomography data and a neural network (3) in the processor; and identifying (S3) a type of choroidal neovascularization in the eye using the volume segments in the processor, the type of choroidal neovascularization comprising one or more of the following: classical choroidal neovascularization (41) and occult choroidal neovascularization (42).

The invention relates to fluorinated modified aflibercept nano-particles and application thereof in eye drops, and belongs to the technical field of nano-drugs. The fluoridation modified aflibercept nano-particles disclosed by the invention are obtained by coupling a perfluoroalkane chain containing a maleimide group and reduced aflibercept. And due to the hydrophobic and oleophobic characteristics of the fluoroalkane chain and the chemical and biological inertness, the modified aflibercept can quickly cross an eye barrier after being dropped into eyes, and the content of VEGF in the eyes is reduced, so that the non-invasive and efficient treatment of CNV is realized. According to the invention, the administration route of aflibercept is innovated, the treatment of choroidal neovascularization can be realized through a non-invasive route in an eye drop administration mode, and the compliance of a patient is greatly improved.

The present invention discloses a method and system for segmenting choroidal neovascularization in optical coherence tomography images. By constructing a segmentation network based on UNet, two paths are provided during downsampling to respectively extract multi-scale global features and multi-scale global features with local semantic information and long-distance dependency information. The features extracted on the two paths are fused to output fused features of each scale, which can fully extract feature information. During upsampling, the fused features and upsampled features of the same scale are enhanced and then fused, which can further focus on the generation of lesion features during the upsampling process. In the upsampling process, lesion boundary information is used as supervisory information to enhance the expression of boundary information, thereby enabling refined segmentation and improving the segmentation effect.

Provided herein are molecules, compositions and methods for treating an ocular disease or disorder, comprising: administering to a subject an aqueous pharmaceutical composition, wherein the composition comprises a molecule, or a pharmaceutically acceptable salt thereof, and having reduced or no antimicrobial activity, wherein the molecule is selected from at least one of structure A, B, C, or D having the R-groups listed for each. The ocular disease or disorder is selected from the group consisting of abnormal angiogenesis, choroidal neovascularization (CNV), age-related macular degeneration (AMD), neovascular (exudative) age-related macular degeneration (nAMD), diabetic retinopathy, retinal vascular permeability, retinal edema, diabetic retinopathy, diabetic macular edema (DME), CNV associated with nAMD, sequela, associated with retinal ischemia, central retinal vein occlusion, and posterior segment neovascularization.

This application discloses the fusion polypeptide AJ007 and its use, and belongs to the art of ophthalmic drugs. This fusion polypeptide AJ007 is formed by linking a TAT membrane-permeable peptide to the tip of a polypeptide HM-1 molecule that inhibits neovascularization. The fusion polypeptide AJ007 was used in the preparation of polypeptide eye drops, and by selecting the formulation of this application, the fusion polypeptide AJ007 was prepared as an eye drop. In the prevention or treatment of wet age-related macular degeneration, the method of administering eye drops effectively avoids various serious side effects and low patient tolerance problems associated with intravitreal injection in clinical practice, and has the advantage of non-invasive treatment. Furthermore, in a laser-induced mouse wAMD model, it showed extremely good efficacy in improving abnormal hyperplasia of choroidal neovascularization, and possesses high clinical therapeutic potential.

The present application relates to the technical field of medical image processing, and particularly relates to an OCT image choroidal neovascularization segmentation method and system. The present application takes TransUNet as a benchmark network, designs an embedded heterogeneous feature alignment module, a curvature KAN guided attention module and a deep-shallow dual-path decoder to build a choroidal neovascularization segmentation model. Through the heterogeneous feature alignment module, the local features extracted by the convolutional neural network and the global context features extracted by the visual extractor are integrated to enable the network to comprehensively extract the features of the OCT image. Through the curvature KAN guided attention module, the attention mechanism is optimized to better obtain the local geometric features of the image. The deep-shallow dual-path decoder processes deep features and shallow features through two parallel decoding paths respectively, thereby significantly enhancing the network's ability to capture small target lesions. The present application effectively improves the segmentation accuracy of the OCT image choroidal neovascularization.

Methods of treating choroidal neovascularization in a patient in need thereof are described herein. In some aspects, the method comprises inhibiting telomerase activity within a biological compartment of the patient. In some instances, inhibiting telomerase activity comprises disposing a telomerase inhibitor and / or disposing an antisense oligonucleotide within the biological compartment of the patient. In some embodiments, the biological compartment of the patient is the eye. Further, in some instances, the patient has neovascular age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity (ROP), corneal neovascularization, and / or neovascular glaucoma.

The present invention belongs to the field of biomedical detection technology, and in particular to a biomarker, a detection kit and an application for detecting high myopia complicated with choroidal neovascularization. The present invention discloses the application of tRF-22 in the preparation of a diagnostic reagent for high myopia complicated with choroidal neovascularization and a diagnostic kit for high myopia complicated with choroidal neovascularization. The present invention is verified by quantitative PCR and finds that tRF-22 is significantly correlated with the occurrence of high myopia complicated with choroidal neovascularization. The present invention utilizes real-time fluorescence quantitative PCR technology, and by detecting the relative content of tRF-22 in aqueous humor, it can be used for the screening of clinical patients with high myopia complicated with choroidal neovascularization, and provides a theoretical basis for the early intervention of high myopia complicated with choroidal neovascularization.

The invention relates to the field of medicine application, and provides application of tanshinone IIA in preparation of a medicine for preventing and / or treating fundus neovascular diseases in subjects, in particular to wet age-related macular degeneration. In addition, the invention also provides application of the tanshinone IIA in preparation of a medicine for preventing and / or treating generation and leakage of choroidal neovascularization of eyes in a subject.

The application discloses application of SELE in treatment of wet age-related macular degeneration. The application research finds that SELE can significantly promote proliferation, migration and tube formation ability of vascular endothelial cells. SELE By inhibiting gene expression or activity, the application can significantly inhibit choroidal neovascularization in a wAMD mouse model, reduce abnormal vascular leakage, effectively reduce ocular inflammatory response, reduce inflammation-mediated vascular damage, target intervention of biological behavior of vascular endothelial cells, and block a key link of pathological angiogenesis. The application provides a novel molecular target for wAMD treatment and breaks the limitation of the existing anti-VEGF therapy.